As of November 6, 2026, Fulgent Genetics, Inc. is a publicly traded company (Nasdaq: FLGT). The largest holder reporting an active stake on Schedule 13D is Ming Hsieh, the chief executive and a director, at 32.26%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, May 27, 2026).
Is this your company?
About to sign with, pay or invest in Fulgent Genetics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Fulgent Genetics, Inc. a real, registered company?
- Fulgent Genetics, Inc. files with the SEC under CIK 1674930 (its SEC filings).
- Its shares are listed under the ticker FLGT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in El Monte, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Fulgent Genetics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Ming Hsieh (filed 2026-05-27).
Who are Fulgent Genetics, Inc.'s owners and officers?
Fulgent Genetics, Inc.: incorporated in Delaware; business address in El Monte, California; industry Services-Medical Laboratories (Schedule 13D/A, 2026-05-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-05-27 | Ming Hsieh | 32.26% |
| Schedule 13D/A, 2026-03-31 | Ming Hsieh | 30.74% |
| Schedule 13G/A, 2026-02-04 | Integrated Core Strategies (US) LLC | 3% |
| Schedule 13G/A, 2025-07-29 | Millennium Management LLC | 4.7% |
| Schedule 13G/A, 2025-07-29 | Millennium Management LLC | 5.6% |
Questions about who owns Fulgent Genetics, Inc.
Who owns Fulgent Genetics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Fulgent Genetics, Inc.: Ming Hsieh (32.26%, Schedule 13D/A, filed 2026-05-27).
When did Ming Hsieh buy into Fulgent Genetics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ming Hsieh on this page is the Schedule 13D/A, filed 2026-03-31, reporting 30.74%; its latest, Schedule 13D/A filed 2026-05-27, reports 32.26%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Fulgent Genetics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Fulgent Genetics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fulgent Genetics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Fulgent Genetics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Ming Hsieh Trust, a 10% owner: 9,018,565 shares (32.3% of shares outstanding), 900,634 held directly and 8,117,931 indirectly, on a joint filing (Form 4/A, 2026-03-31).
- , the chief executive and a director: 1,108,768 shares (4.0% of shares outstanding), 885,952 held directly and 222,816 indirectly (Form 4, 2026-09-03).
- , the chief scientific officer: 984,472 shares (3.5% of shares outstanding) (Form 4, 2026-10-28).
- , the president and chief operating officer: 576,379 shares (2.1% of shares outstanding), 355,563 held directly and 220,816 indirectly (Form 4, 2026-10-28).
- , the chief financial officer and treasurer: 353,795 shares (1.3% of shares outstanding) (Form 4, 2026-10-28).
Shares outstanding: 27,939,000 as of 2026-11-02, from the company's latest SEC cover page.
How much has Fulgent Genetics, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-03-17).
Keep reading
More on Fulgent Genetics, Inc. and the records around it.
Fulgent Genetics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- Integrated Core Strategies (US) LLC also filed stake reports on 121 other companies: StepStone Group Inc. (Nov 2026), Catalyst Acquisition Corp. (Nov 2026), RxSight, Inc. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/fulgent-genetics